potential therapy – Page 3 – Communicable Diseases Research

Clinical features of Danon disease and insights gained from LAMP-2 deficiency models

Review article

Published on 2021-11-012022-10-05
Journal: Trends in cardiovascular medicine [Category] 비임상,

Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System

Immunology

Published on 2021-10-182022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

[키워드] acute respiratory syndrome airway Airway organoids anti-RBD approved binding caused coronavirus Coronavirus disease 2019 COVID-19 develop domain Drug screening drugs Effect effective Efficacy Emergency use authorization epithelial Epitopes Ex vivo Generation immune in vivo Infection injection intrinsic morphology mouse model Mutation mutations Organoid polyclonal antibody Potential potential therapy Receptor-binding domain respiratory infectious disease Respiratory tract infections SARS-CoV-2 SARS-COV-2 infection Screening serum Side effect Side effects spread of COVID-19 System tested Testing tissue damage Treatment two-dimensional US FDA Vaccine viral escape viral infection viral neutralization viral strain virus
[DOI] 10.3389/fimmu.2021.689065 PMC 바로가기 [Article Type] Immunology

Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan

Clinical Trial

Published on 2021-09-272022-10-04
Journal: BMC Infectious Diseases [Category] SARS, 임상,

[키워드] Analysis ANOVA applied can be used Chi-square clinical status Complication conducted Convalescent CP recipient convalescent plasma Convalescent plasma (CP) correlated COVID pneumonia COVID-19 COVID-19 pandemic COVID-19 patient criterion Critical critical cases Cytokine storm death disease Disease progression Endpoint Enrollment expired Fisher’s exact test FIVE hospitalized patients interquartile ranges invasive ventilation lung infiltrates lung infiltration Mann-Whitney U test median median age median time multiorgan failure non-randomized onset of symptom open label oxygen saturation parameter Patient patients potential therapy recipient recipients registration date Result Safe SARS CoV2 infection severe adverse events severe patients severity SOFA SOFA score SPSS Study design transfused Treatment Trial Trial registration ventilator
[DOI] 10.1186/s12879-021-06451-7 PMC 바로가기 [Article Type] Clinical Trial

Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies

Research

Published on 2021-09-202022-10-30
Journal: Molecular Biomedicine [Category] COVID-19,

Therapeutic Potential of Annexins in Sepsis and COVID-19

Pharmacology

Published on 2021-09-092022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] adaptive analogue animal model Annexin annexin (A1, A2 and A5) Anti-inflammatory caused Cell cell membrane clinical trial Coagulation condition COVID-19 demonstrated disease Effect Efficacy healthcare Human Immunity IMPROVE Inflammation Inflammatory inflammatory mediator inhibit investigated involved Ischemia ischemic injury mechanism modulation mortality rate MOST Myocardial infarction organ function outcome pathophysiology Patient peptide phagocytosis physiological platelet activation positive Potential potential therapies potential therapy Prevalence PROTECT Protective reduce reduce mortality reperfusion injury Research Safety SARS-COV-2 infection Sepsis severe COVID-19 patients shielding Support systemic effects therapeutic agent Treatment
[DOI] 10.3389/fphar.2021.735472 PMC 바로가기 [Article Type] Pharmacology

A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients

Pharmacology

Published on 2021-09-022022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 95% CI 95% confidence interval Activation all-cause mortality anticoagulation bleeding coronavirus disease COVID-19 COVID-19 patients dose effective Effectiveness Efficacy Endpoint evaluated hazard heparin heparin treatment heparins higher risk Hospital stay hospitalized COVID-19 patients increased risk LMWH LOS low molecular weight major bleeding Meta-analysis Mortality no difference Observational cohort study Patient patients performed potential therapy Prophylactic prophylactic dose Randomized controlled trial Ratio RCT reduced reducing mortality Registration reported review SARS-CoV2 secondary subgroup analysis systematic review therapeutic dose Thromboembolism Treatment unfractionated heparin was performed weight
[DOI] 10.3389/fphar.2021.698008 PMC 바로가기 [Article Type] Pharmacology

Targeting of Protein’s Messenger RNA for Viral Replication, Assembly and Release in SARS-CoV-2 Using Whole Genomic Data From South Africa: Therapeutic Potentials of Cannabis Sativa L

Pharmacology

Published on 2021-09-022022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] activity Analysis assembly attack bat binding affinity cannabinol cannabis Cannabis sativa China Clinical studies coding computational tools country COVID-19 docking envelope Genome glycoprotein homology IBV implicated in viral Interaction investigated Italy MERS-CoV messenger MHV Middle East mouse mRNA mRNAs Nucleocapsid phosphoprotein ORF1ab other coronaviruses Patient phytocannabinoids Potential potential therapy Protein Release Replication respiratory RNA SARS CoV SARS-CoV-2 South South Africa Spain Spectroscopy Spread surface targeting translation United States viral nucleotide whole genome
[DOI] 10.3389/fphar.2021.736511 PMC 바로가기 [Article Type] Pharmacology

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

COVID-19 치료를 위한 SARS-CoV-2-중화 단일클론항체

Review

Published on 2021-09-022022-09-11
Journal: The Cochrane database of systematic reviews [Category] SARS, 변종, 임상,

[키워드] 95 % CI 95% CI 95% confidence interval Admission adverse event adverse events AEs all-cause mortality antibody approach average age B cell B cells bamlanivimab Blinding Casirivimab certainty certainty of evidence checked clinical Cochrane COVID-19 Study Register Combination combination therapy conducted coronavirus disease Coronavirus disease 2019 COVID-19 Data collection database death decrease dose Effectiveness etesevimab evaluated event Evidence excluded first test GRADE hospital Hospital admission Hospital admissions hospital discharge hospitalised Host Human identify Imdevimab IMV individual individuals with COVID-19 initial Intervention Invasive mechanical ventilation investigated lack life limitation mAb mAbs maintain moderate monoclonal antibodies monoclonal antibody Mortality NCT04427501 neutralising mAbs nine no effect non-hospitalised occurred outcome oxygen Oxygen requirement participant Participants patients with COVID-19 people with COVID-19 Placebo placebo group placebo treatment potential therapy progression Prophylactic provided Quality of life randomised controlled trial RCT reduce regdanvimab reported risk risk of bia risk ratio RoB2 SAE SAEs Sample size SARS-CoV-2 variant SARS-CoV-2 variants searched Selection Serious Adverse Event Serious Adverse Events severe symptom severe symptoms slight increase Sotrovimab submission Symptom systematic review target the placebo group treat treated Treatment treatment of COVID-19 usual care usual care alone
[DOI] 10.1002/14651858.CD013825.pub2 PMC 바로가기 [Article Type] Review

Efficacy of convalescent plasma for treatment of COVID-19 in Uganda

Randomized Controlled Trial

Published on 2021-08-012022-10-04
Journal: BMJ Open Respiratory Research [Category] SARS, 임상,

[키워드] African Arm benefit CCP CCP therapy clinical clinical status convalescent plasma COVID-19 deaths defined determine Disease progression disease severity Efficacy hospitalised Improvements male median median age Mortality not different outcome oxygen oxygen saturation Patient patients plasma positive potential therapy Primary outcome progression randomised receive respiratory infection SARS-CoV-2 scale secondary secondary outcome Standard of care statistically significant difference subgroups of patient Symptom symptom resolution the median time transcriptase Treatment Trial Uganda viral clearance viral infection Virological WHO
[DOI] 10.1136/bmjresp-2021-001017 PMC 바로가기 [Article Type] Randomized Controlled Trial

Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2

전장 재조합 HSP-D는 SARS-COV-2를 결합하고 억제한다

Article

Published on 2021-07-282022-09-10
Journal: Biomolecules [Category] Coronavirus, SARS, 변종,

[키워드] ACE2 aggregation Anti-inflammatory Anti-viral bind binding binding assay Binding assays bronchoalveolar lavage sample bronchoalveolar lavage samples Caco-2 Caco-2 cell Caco-2 cells cells clearance Combined Concentration COVID-19 COVID-19 patient COVID-19 patients Critical driven by ELISA ELISAs epithelial evaluated facilitate followed by gel electrophoresis glycosylated healthy control healthy controls host cell host cells immune defense immune response in vitro induce inhibit initiate invading pathogen invading pathogens lung lung type II pneumocytes Lungs median member Pathogens Patient performed potential therapy Protein pulmonary recognize recombinant Replication reported Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication silver SP-D spike-protein staining Structure surfactant the SARS-CoV-2 type II pneumocytes variants Viral viral replication virus Virus Disease virus replication viruses were measured
[DOI] 10.3390/biom11081114 PMC 바로가기 [Article Type] Article